Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO‐D registry

Patients with advanced heart failure (AHF) who are not candidates to advanced therapies have poor prognosis. Some trials have shown that intermittent levosimendan can reduce HF hospitalizations in AHF in the short term. In this real‐life registry, we describe the patterns of use, safety and factors related to the response to intermittent levosimendan infusions in AHF patients not candidates to advanced therapies.

[1]  K. Anstrom,et al.  Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2021, JAMA cardiology.

[2]  M. Martínez‐Sellés,et al.  Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study , 2021, ESC heart failure.

[3]  P. Ponikowski,et al.  N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. , 2020, JACC. Heart failure.

[4]  S. Verma,et al.  Two Tales: One Story. EMPEROR-Reduced and DAPA-HF. , 2020, Circulation.

[5]  J. F. Jiménez,et al.  Levosimendán como terapia puente a trasplante cardiaco en pacientes con insuficiencia cardiaca avanzada , 2020 .

[6]  F. Arribas Ynsaurriaga,et al.  Levosimendan as bridge to transplant in patients with advanced heart failure. , 2020, Revista espanola de cardiologia.

[7]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[8]  L. Stevenson,et al.  Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry. , 2019, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  G. Malfatto,et al.  Scheduled intermittent inotropes for Ambulatory Advanced Heart Failure. The RELEVANT-HF multicentre collaboration. , 2018, International journal of cardiology.

[10]  M. Grau,et al.  Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION‐HEART multicentre randomised trial , 2018, European journal of heart failure.

[11]  Akshay S. Desai,et al.  Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction , 2017, Journal of the American Heart Association.

[12]  Akshay S. Desai,et al.  Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial , 2016, European journal of heart failure.

[13]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[14]  H. Ulmer,et al.  Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial , 2014, European journal of heart failure.

[15]  B. Massie,et al.  Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. , 2013, JACC. Heart failure.

[16]  M. Costanzo,et al.  Characteristics of "Stage D" heart failure: insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM). , 2008, American heart journal.

[17]  Javed Butler,et al.  Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. , 2007, Journal of the American College of Cardiology.

[18]  T. R. I. Nvestigators.  A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE , 2001 .